Searchable abstracts of presentations at key conferences on calcified tissues

ba0002op4 | (1) | ICCBH2013

A new start-codon in IFITM5 causes osteogenesis imperfecta type V

Semler Oliver , Hoyer-Kuhn Heike , Garbes Lutz , Netzer Christian , Schoenau Eckhard

Background: Osteogenesis imperfecta (OI) is a rare disease characterized by increased fracture rate and bone deformities. Patients are classified by phenotype and most are affected by mutations in COL1A1/2.Patients with OI type V present with specific clinical symptoms including hyperplastic callus formation, only mildly decreased height, metaphyseal lines and a calcification of the membrane interossea of the forearm. The disease causing mutation for OI ...

ba0001pp136 | Cancer and bone: basic, translational and clinical | ECTS2013

Modulation of macrophage activation status by bisphosphonates and breast cancer cells

Sousa Sofia , Monkkonen Jukka , Maatta Jorma

Tumour stromal macrophages differentiate into tumour associated macrophages (TAMs), with characteristics resembling the immunosuppressive M2 polarization instead of the pro-inflammatory M1. TAMs have a central role in promoting tumour vascularization, cancer cell dissemination and suppression of anti-cancer immune response. Cancer cell dissemination leads to metastasis formation which, e.g. in breast cancer often happens in bone marrow. We have studied the in vitro mo...

ba0004p195 | (1) | ICCBH2015

Increase of bone mineral density in patients with osteogenesis imperfecta treated with pamidronate disodium.

de Menezes Filho Hamilton Cabral , de Brito Pupo Joyce , de Magalhaes Velasco Bastos Paula , Ae Kim Chong , Bertola Debora Romeo , Ito Simone Sakura , dos Santos Tiago Jeronimo , Setian Nuvarte , Damiani Durval

Objective: This study aimed to evaluate the efficacy of the treatment with pamidronate disodium (PD) with respect to the increase of bone mineral density (BMD) in patients with osteogenesis imperfecta (OI).Patients and methods: We evaluated nine patients (six boys) with OI (four with type III, four with type IV, one with type I) treated with PD from 4.68 to 7.92 years (mean±S.D.: 6.75±1.38 years). Intravenous PD was administered ...

ba0001pp31 | Bone biomechanics and quality | ECTS2013

A GWAS in an extreme high bone mass population shows excess signal from genes associated with BMD in the normal population

Gregson Celia L , Leo Leo Paul J , Clark Graeme R , Smith George Davey , Brown Matthew A , Tobias Jon H , Duncan Duncan Emma L

Extreme high bone mass (HBM) may be monogenic (e.g. due to mutations in SOST or LRP5) or polygenic, due to variants in the same genes determining bone mineral density (BMD) as found in the general population. We aimed to determine the genetic cause underlying HBM in an extreme HBM population.258 unexplained HBM cases (defined as L1 Z-score ≥+3.2 plus total hip Z-score ≥+1.2, or total hip Z-score ≥+3.2 and L1 <...

ba0007p9 | (1) | ICCBH2019

Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study

Duckham Rachel L , Hyde Natalie K , Brennan-Olsen Sharon L , Hesketh Kylie , Teo Wei-Peng , Rodda Christine , Walsh Adam , Laing Emma M , Lewis Richard D

Objective: Autism Spectrum Disorder (ASD) is associated with lower bone mass in children. Physical activity and nutrition influence bone pathophysiology, and differences in these lifestyle factors are observed between children with vs. without ASD; however, whether these factors contribute to bone differences is unknown. We examined if: 1) differences existed in bone mineral density (BMD), content (BMC), or bone geometry in boys with vs without ASD and 2) whether physical acti...

ba0001pp446 | Osteoporosis: treatment | ECTS2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate– a randomized placebo-controlled trial

Chapurlat Roland , De Villiers Tobias , Bonnick Sydney , Odio Alberto , Palacios Santiago , Scott Boyd , De Tilleghem Celine Le Bailly , DaSilva Carolyn , Leung Albert , Gurner Deborah

Odanacatib (ODN) is an orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN 50mg once weekly on BMD, bone turnover markers and safety in patients previously treated with alendronate (ALN).This was a randomized, double-blind, placebo-controlled, 24-month study. The primary endpoint was % change from baseline at month 24 of femoral neck (FN) BMD. Postmenopausal women (...

ba0002p102 | (1) | ICCBH2013

Influence of nutritional status in the bone mass assessed by quantitative ultrasonography of boys

de Oliveira Barbeta Vinicius Justino , Bertapelli Fabio , Goncalves Ezequiel Moreira , Krahenbuhl Tathyane , de Barros Ramalho Luiz Carlos , Martin Juan Eduardo Samur-San , Ribeiro Roberto Regis , Guerra-Junior Gil

The childhood is an important period for bone mass acquisition, and this tissue may be influenced by the nutritional status. However, the relation between the nutritional status and the bone parameters of quantitative ultrasound (QUS) remains unclear. The aim of this study was to verify the influence of nutritional status on bone mass assessed by QUS in male children from 7 to 10 years old. The sample consisted of 461 Brazilians pre-pubertal schoolchildren (8.30±1.13 year...

ba0005oc3.1 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Effect of odanacatib on bone density and estimated bone strength in postmenopausal women: a CT-based sub-study of the phase 3 long-term odanacatib fracture trial (LOFT)

Langdahl Bente , De Villiers Tobias , Keaveny Tony M , Engelke Klaus , Genant Harry , Ather Shabana , Giezek Hilde , Lombardi Antonio , Leung Albert , de Papp Anne

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk. This imaging sub-study primarily investigated the effect of ODN on volumetric BMD (vBMD) of the lumbar spine (LS) and total hip (TH) using quantitative computed tomography (QCT).Women aged ≥65 without baseline radiographic vertebra...